8/18/2014 8:04:21 AM
TUCKER, Ga. & ROCKVILLE, Md.--(BUSINESS WIRE)--Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract research and manufacturing organization to the biopharmaceutical industry, announced today an agreement whereby ABL will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy. Expression Therapeutics’ recombinant factor VIII platform generates 100-fold greater expression than current products. ABL will adapt the current cell line to grow in chemically defined, animal origin-free media, and conduct optimization studies of cell growth conditions to support large scale production in a bioreactor-based process.
Help employers find you! Check out all the jobs and post your resume.
comments powered by